A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Ignace Vergote, Florian Heitz, Paul Buderath, Matthew Powell, Jalid Sehouli, Christine M. Lee, Anne Hamilton, James Fiorica, Kathleen N. Moore, Michael Teneriello, Lisa Golden, Wei Zhang, Celine Pitou, Robert Bell, Robert Campbell, Daphne L. Farrington, Katherine Bell-McGuinn, Robert M. Wenham

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint Dive into the research topics of 'A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences